Meeder Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $196K | Buy |
1,071
+855
| +396% | +$158K | 0.01% | 300 |
|
|
2025
Q4 | $38K | Buy |
216
+165
| +324% | +$27K | ﹤0.01% | 438 |
|
|
2025
Q3 | $7.14K | Buy |
51
+1
| +2% | +$135 | ﹤0.01% | 611 |
|
|
2025
Q2 | $6.28K | Buy |
50
+12
| +32% | +$1.5K | ﹤0.01% | 690 |
|
|
2025
Q1 | $5.2K | Sell |
38
-16
| -30% | -$2.29K | ﹤0.01% | 759 |
|
|
2024
Q4 | $8.26K | Sell |
54
-900
| -94% | -$152K | ﹤0.01% | 744 |
|
|
2024
Q3 | $185K | Sell |
954
-319
| -25% | -$66.7K | 0.01% | 229 |
|
|
2024
Q2 | $295K | Buy |
1,273
+1,241
| +3,878% | +$270K | 0.02% | 180 |
|
|
2024
Q1 | $6.9K | Buy |
+32
| New | +$7.49K | ﹤0.01% | 603 |
|
|
2023
Q3 | – | Sell |
-12,210
| Closed | -$3.48M | – | 499 |
|
|
2023
Q2 | $3.48M | Buy |
12,210
+8,663
| +244% | +$2.58M | 0.25% | 89 |
|
|
2023
Q1 | $986K | Sell |
3,547
-4,168
| -54% | -$1.15M | 0.08% | 172 |
|
|
2022
Q4 | $2.14M | Buy |
7,715
+1,316
| +21% | +$372K | 0.19% | 127 |
|
|
2022
Q3 | $1.71M | Buy |
6,399
+5,465
| +585% | +$1.16M | 0.1% | 171 |
|
|
2022
Q2 | $190K | Sell |
934
-307
| -25% | -$62.8K | 0.01% | 612 |
|
|
2022
Q1 | $261K | Buy |
+1,241
| New | +$270K | 0.01% | 600 |
|
|
2021
Q4 | – | Sell |
-27,178
| Closed | -$7.69M | – | 1290 |
|
|
2021
Q3 | $7.69M | Buy |
27,178
+6,663
| +32% | +$2.18M | 0.4% | 65 |
|
|
2021
Q2 | $7.1M | Buy |
20,515
+15,712
| +327% | +$4.76M | 0.33% | 70 |
|
|
2021
Q1 | $1.34M | Buy |
4,803
+3,882
| +421% | +$1.05M | 0.07% | 219 |
|
|
2020
Q4 | $226K | Sell |
921
-18,520
| -95% | -$4.78M | 0.05% | 288 |
|
|
2020
Q3 | $5.52M | Buy |
19,441
+4,676
| +32% | +$1.3M | 0.36% | 64 |
|
|
2020
Q2 | $3.95M | Buy |
14,765
+1,959
| +15% | +$589K | 0.26% | 84 |
|
|
2020
Q1 | $4.05M | Sell |
12,806
-15,499
| -55% | -$4.7M | 0.31% | 71 |
|
|
2019
Q4 | $8.4M | Sell |
28,305
-8,708
| -24% | -$2.42M | 0.51% | 56 |
|
|
2019
Q3 | $8.62M | Buy |
37,013
+3,284
| +10% | +$765K | 0.57% | 52 |
|
|
2019
Q2 | $7.89M | Buy |
33,729
+9,916
| +42% | +$2.29M | 0.55% | 57 |
|
|
2019
Q1 | $5.63M | Buy |
23,813
+1,895
| +9% | +$597K | 0.44% | 67 |
|
|
2018
Q4 | $6.6M | Buy |
21,918
+1,779
| +9% | +$568K | 0.59% | 46 |
|
|
2018
Q3 | $7.12M | Sell |
20,139
-2,189
| -10% | -$754K | 0.53% | 56 |
|
|
2018
Q2 | $6.48M | Buy |
22,328
+5,098
| +30% | +$1.43M | 0.56% | 47 |
|
|
2018
Q1 | $4.72M | Buy |
17,230
+1,692
| +11% | +$525K | 0.44% | 61 |
|
|
2017
Q4 | $4.95M | Buy |
15,538
+5,785
| +59% | +$1.86M | 0.42% | 56 |
|
|
2017
Q3 | $3.05M | Buy |
9,753
+3,826
| +65% | +$1.13M | 0.33% | 75 |
|
|
2017
Q2 | $1.61M | Sell |
5,927
-3,780
| -39% | -$1,000K | 0.15% | 142 |
|
|
2017
Q1 | $2.65M | Buy |
9,707
+4,475
| +86% | +$1.27M | 0.24% | 98 |
|
|
2016
Q4 | $1.48M | Buy |
5,232
+458
| +10% | +$136K | 0.14% | 161 |
|
|
2016
Q3 | $1.49M | Sell |
4,774
-1,659
| -26% | -$491K | 0.13% | 181 |
|
|
2016
Q2 | $1.56M | Buy |
6,433
+619
| +11% | +$163K | 0.15% | 147 |
|
|
2016
Q1 | $1.51M | Buy |
5,814
+4,263
| +275% | +$1.13M | 0.14% | 157 |
|
|
2015
Q4 | $475K | Sell |
1,551
-11,013
| -88% | -$3.16M | 0.04% | 338 |
|
|
2015
Q3 | $3.67M | Buy |
12,564
+2,599
| +26% | +$858K | 0.36% | 74 |
|
|
2015
Q2 | $4.03M | Buy |
9,965
+7,765
| +353% | +$3.12M | 0.41% | 46 |
|
|
2015
Q1 | $929K | Buy |
+2,200
| New | +$867K | 0.1% | 234 |
|
Other funds holding BIIB
VCM
VPM
Meeder Asset Management's BIIB Position: Q1 2026 in Review
Meeder Asset Management increased its Biogen (BIIB) stake by 396% in Q1 2026, buying an estimated $158K and bringing the position to 1,071 shares worth $196K. The position accounts for 0.01% of the portfolio, ranked #300.
Meeder Asset Management first reported a position in BIIB in Q1 2015 and has held it in 42 quarters since. The position peaked at $8.62M in Q3 2019. 1,005 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Meeder Asset Management held 1,071 shares of Biogen worth $196K as of Q1 2026.
- Meeder Asset Management bought 855 Biogen shares in Q1 2026, an estimated $158K.
- Biogen made up 0.01% of Meeder Asset Management's portfolio in Q1 2026, its #300 holding.
- Meeder Asset Management first reported a position in Biogen in Q1 2015 and has held it in 42 quarters since.
- Meeder Asset Management's Biogen position peaked at $8.62M in Q3 2019.
- 1,005 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.